Athenex, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2003-01-01

Employees: 280

Market Cap: -

Website: http://www.athenex.com

Clinical Trials

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: Oraxol
Biological: Pembrolizumab

First Posted Date: 2018-07-17

Last Posted Date: 2023-05-19

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 34

Registration Number: NCT03588039

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

Phase 1

Completed

Conditions: Actinic Keratoses

Interventions: Drug: KX2-391 Ointment 1%

First Posted Date: 2018-07-03

Last Posted Date: 2019-12-09

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 18

Registration Number: NCT03575780

Locations: 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Phase 2

Completed

Conditions: Angiosarcoma of Skin

Interventions: Drug: Oraxol

First Posted Date: 2018-06-04

Last Posted Date: 2023-05-19

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 48

Registration Number: NCT03544567

Locations: 🇺🇸
University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 7 locations

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Phase 1

Completed

Conditions: Breastcancer

Interventions: Drug: Oraxol

First Posted Date: 2017-05-24

Last Posted Date: 2022-03-18

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 28

Registration Number: NCT03165955

Locations: 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳
Shuang Ho Hospital, Taipei, Taiwan
🇨🇳
Tri-Service General Hospital, Taipei, Taiwan

and more 3 locations

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Phase 1

Conditions: Gastric Cancer
Esophageal Cancer
Gastro-esophageal Cancer

Interventions: Drug: Oraxol
Drug: Ramucirumab

First Posted Date: 2016-11-22

Last Posted Date: 2022-02-16

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 36

Registration Number: NCT02970539

Locations: 🇺🇸
CTRC-UT, San Antonio, Texas, United States
🇨🇳
Lotung Poh-Ai Hospital, Yilan, Taiwan
🇨🇳
Tri-Service General Hospital, Taipei, Taiwan

and more 2 locations

A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

Phase 1

Conditions: Solid Tumor

Interventions: Drug: Oradoxel

First Posted Date: 2016-11-15

Last Posted Date: 2019-10-17

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 24

Registration Number: NCT02963168

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Oraxol

First Posted Date: 2016-04-06

Last Posted Date: 2021-09-13

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 38

Registration Number: NCT02730481

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cancer Therapy &Research Center @ UTHSCSA, San Antonio, Texas, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: IV paclitaxel
Drug: Oraxol

First Posted Date: 2015-11-03

Last Posted Date: 2022-08-03

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 402

Registration Number: NCT02594371

Locations: 🇦🇷
CAIPO, Tucumán, Argentina
🇨🇴
Instituto Nacional de Cancerología E.S.E., Bogota, Colombia
🇨🇱
Fundación Arturo López Pérez, Santiago de Chile, Chile

and more 41 locations

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: KX2-391 Ointment

First Posted Date: 2015-01-13

Last Posted Date: 2018-07-06

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 29

Registration Number: NCT02337205

Locations: 🇺🇸
DermResearch, Inc., Austin, Texas, United States

Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies

Phase 1

Completed

Conditions: Advance Malignancies

Interventions: Drug: KX2-361

First Posted Date: 2014-12-29

Last Posted Date: 2019-01-15

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 29

Registration Number: NCT02326441

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸
UTHSCSA Cancer Therapy and Research Center, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy